Nicholas Dracopoli, Ph.D. is Vice President and Head of Oncology Diagnostics at Janssen Research & Development, LLC. In this role, he is responsible for building and leading the Oncology Diagnostics group, which is focused on developing all companion and complementary diagnostics in our oncology development portfolio.
Nicholas joined Janssen Research & Development in 2007 as Vice President, Oncology Biomarkers. Since then, he has led the growth of the Translational Science, with dedicated teams for each Disease Area Stronghold (DAS), as well as three cross-DAS functional groups (Bioinformatics, Molecular Pathology and Biomarker Operations) that support the core DAS translational research strategies.
Prior to Janssen Research & Development, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb and also spent five years in the biotechnology industry at Sequana Therapeutics.
Nicholas obtained his bachelor’s degree and doctorate from the University of London and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center in New York City and the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center and as a Section Chief at the National Center for Human Genome Research at the National Institutes of Health, Bethesda, Maryland.
Nicholas has authored more than 70 scientific publications and has extensive experience in the fields of genomics, molecular biology and cancer research.